Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis. From December 1996 through May 2024, 82 ...
An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its ...
VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results